Business Context and Reporting Period
Company: Longeveron Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 17, 2024 (Event Date)
Closing Date: June 18, 2024
Context: The Company entered into inducement letter agreements with holders of existing Series D warrants to facilitate the exercise of those warrants in exchange for new warrants. This transaction was executed to raise capital for ongoing clinical and regulatory development.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $4.4 million (inclusive of payment consideration for new warrants, before deducting fees and expenses).
- Warrant Exercise: Holders agreed to exercise existing warrants for 1,697,891 shares at an exercise price of $2.35 per share.
- New Warrants Issued: The Company issued new unregistered warrants to purchase up to 3,395,782 shares at an exercise price of $2.50 per share.
- Placement Agent Fees:
- Cash fee: 7.0% of gross proceeds.
- Management fee: 1.0% of gross proceeds.
- Out-of-pocket expenses: $35,000 (non-accountable) + $50,000 (legal/other) + $15,950 (clearing fee).
- Warrant compensation: Placement agent received warrants for 118,852 shares (Transaction) and 49,130 shares (Prior).
- Use of Proceeds: Clinical and regulatory development of Lomecel-B (for HLHS and Alzheimer's disease), regulatory approvals, capital expenditures, working capital, and general corporate purposes.
Material Changes and Agreements
The filing details a material definitive agreement involving the following key terms and restrictions:
- Inducement Transaction: Existing warrant holders received new warrants (24-month term, immediately exercisable) in consideration for exercising their original warrants for cash.
- Registration Rights: The Company agreed to file a resale registration statement (Form S-3 or S-1) within 20 calendar days and use commercially reasonable efforts to have it declared effective within 45 calendar days.
- Issuance Restrictions:
- 15-day blackout period on issuing new Common Stock or equivalents following the closing.
- One-year prohibition on entering into agreements for Variable Rate Transactions.
- Future Fees: Upon future cash exercise of the New Warrants, the Company must pay the placement agent an additional 7.0% cash fee, 1.0% management fee, and issue additional warrants equal to 7.0% of the shares underlying the exercised warrants.
Guidance, Outlook, and Risks
Management Commentary: The transaction is intended to support the development pipeline for Lomecel-B. The Company is an emerging growth company.
Risks and Contingencies:
- Unregistered Securities: New warrants and shares were sold without registration under Section 4(a)(2) and Rule 506 of the Securities Act.
- Dilution: The issuance of new warrants and potential future exercises will increase the number of outstanding shares.
- Future Obligations: The Company has committed to future cash payments and warrant issuances to the placement agent upon the exercise of the new warrants.
- Limitations on Disclosure: The filing explicitly states that representations and warranties in the agreements are for the benefit of the parties and should not be relied upon as factual disclosures regarding the Company's general condition.
Investor Verification Checklist
- Verify the effective date of the resale registration statement (Form S-3 or S-1) for the New Warrant Shares.
- Confirm the exact net proceeds after deducting all placement agent fees and expenses.
- Monitor the Company's compliance with the 15-day issuance blackout period and the one-year Variable Rate Transaction prohibition.
- Review the terms of the Placement Agent Warrants (exercise prices of $3.25 and $2.9375) and their impact on future dilution.
- Assess the progress of Lomecel-B clinical trials for HLHS and Alzheimer's disease as the primary use of funds.